Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole or fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes or by blocking the use of estrogen by the tumor cells. Giving hormone therapy before surgery may be an effective treatment for breast cancer. It is not yet known whether anastrozole is more effective than fulvestrant when given before surgery in treating women with breast cancer.

PURPOSE: This randomized phase II trial is studying anastrozole to see how well it works compared with fulvestrant in treating postmenopausal women with stage II or stage III breast cancer that can be removed by surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

NCT00871858

Breast Cancer

COMPLETED PHASE2

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

NCT00256698

Breast Cancer

COMPLETED PHASE3

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115

Invasive Breast Cancer

COMPLETED PHASE2

Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery

NCT01953588

Estrogen Receptor-positive Breast Cancer HER2-negative Breast Cancer Invasive Ductal Breast Carcinoma +6 more

ACTIVE_NOT_RECRUITING PHASE3

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

NCT00075764

Breast Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To compare the clinical response rates (complete and partial responses) at 6 months in postmenopausal women with operable stage II or III breast cancer treated with neoadjuvant anastrozole vs fulvestrant.

Secondary

* To compare the breast surgery conservation rate in patients treated with these drugs.
* To correlate imaging findings by mammography, ultrasonography, and MRI with histological and clinical response in these patients and with sensitivity profile to these drugs.
* To compare histological response in patients treated with these drugs.
* To define criteria appropriate for neoadjuvant hormonal therapy.
* To correlate baseline molecular characteristics and modifications during treatment with response in these patients.
* To compare the tolerability of these drugs in these patients.
* To compare the serum proteomic profile of patients treated with these drugs.
* To correlate 3-year event-free and overall survival rates with clinical and histological response in these patients.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral anastrozole once daily for 4-6 months in the absence of clinical progression.
* Arm II: Patients receive fulvestrant intramuscularly on days 1, 15, and 29 in the first month and then every 28 days in each subsequent month. Treatment continues for 4-6 months in the absence of clinical progression.

Patients in both arms then undergo surgery and radiotherapy according to institutional guidelines. Patients then receive adjuvant hormonal therapy for at least 5 years.

After completion of study therapy, patients are followed periodically for up to 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Anastrozole

Group Type EXPERIMENTAL

anastrozole

Intervention Type DRUG

1 mg/day for either 4 months or 6 months depending on the clinical evaluation

Arm B

Fulvestrant

Group Type EXPERIMENTAL

fulvestrant

Intervention Type DRUG

500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anastrozole

1 mg/day for either 4 months or 6 months depending on the clinical evaluation

Intervention Type DRUG

fulvestrant

500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed infiltrating breast adenocarcinoma

* Large, operable tumor
* Stage T2 (≥ 3 cm) or T3-T4 (excluding inflammatory disease), N0-N3, M0 disease

* No bilateral inflammatory breast tumors (T4d \[PEV-2 or PEV-3\])
* Elston-Ellis grade I or II and mitotic index 1 or 2 (if \< 65 years of age)
* At least 1 embedded and 1 frozen biopsy sample available
* No multifocal or multicentric tumors for which breast conservation cannot be envisaged
* No ErbB2-overexpressing tumors (HER2 3+ by IHC OR HER2 2+ by IHC and FISH positive)
* Hormone receptor status:

* Estrogen receptor and/or progesterone receptor positive tumor (\> 10%) as assessed by IHC

PATIENT CHARACTERISTICS:

* Female
* Postmenopausal
* ECOG performance status 0-2
* ANC ≥ 2,000/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 10 g/dL
* Creatinine ≤ 1.5 times upper limit of normal (ULN)
* Total bilirubin ≤ 1.25 times ULN
* AST and ALT ≤ 1.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* No other cancer within the past 10 years, except basal cell skin cancer or previously treated carcinoma in situ of the cervix
* No uncontrolled cardiac pathology, including any of the following:

* Angina pectoris
* Congestive cardiac insufficiency
* Myocardial infarction within the past 3 months
* No known history of hemorrhagic diathesis
* No known allergy to the study drugs or their excipients
* No congenital galactosemia, glucose malabsorption syndrome, or lactase deficiency
* No chronic somatic or psychiatric illness with pejorative prognosis
* No geographical, social, or psychiatric condition that would preclude study compliance and follow-up schedule
* No individual deprived of liberty or placed under the authority of a tutor

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy, hormonal therapy, or any targeted treatment for the breast tumor
* At least 2 weeks since prior hormone replacement therapy for menopause
* No concurrent long-term anticoagulation treatment
* No concurrent participation on another therapeutic trial involving an experimental molecule

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No